Pre-order Enquiry
Request Free Sample
Healthcare
Aerospace & Defence
Agriculture
Automations
Chemicals & Advanced Materials
Food & Beverages
Information & Communication Technology
Oil & Gas
Power & Energy
Mosquito-borne Diseases Drug Development Pipeline Review, 2018
Summary
This report provides an overview of the pipeline landscape for mosquito-borne diseases and comprehensive information on the therapeutics under development and key players involved in therapeutic development for West Nile virus infections, Japanese encephalitis, yellow fever and malaria. It also features dormant and discontinued products.
West Nile infection, Japanese encephalitis and yellow fever are all caused by flaviviruses, whereas malaria is caused by a parasite (Plasmodium). Symptoms of West Nile infection include a fever, headache, body aches, skin rash, and swollen lymph glands. There are 18 products in development for this indication.
Japanese encephalitis affects the membranes around the brain. Symptoms include fever, headache, muscle pain, diarrhea, seizures, muscle weakness and paralysis. There are 17 products in development for this indication.
Yellow fever is an acute systemic illness (hemorrhagic fever). Symptoms include irregular heartbeats, bleeding, vomiting, coma, delirium, fever, headache and muscle aches. There are 15 products in development for this indication.
Malaria is a life-threatening blood disease. Symptoms may include fever, chills, headache, sweats, fatigue, enlarged spleen, nausea and vomiting. There are 206 products in development for this indication.
Molecular targets acted on by products in development for mosquito-borne diseases include interferon receptors, toll-like receptors and pathogen proteins such as Plasmodium falciparum merozoite surface proteins. Companies operating in this pipeline space include Sanaria, Medigen and Ology Bioservices.
Scope
- Which companies are the most active within each pipeline?
- Which pharmaceutical approaches are the most prominent at each stage of the pipeline and within each indication?
- To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies?
- What are the most important R&D milestones and data publications to have happened in this disease area?
Reasons to buy
- Understand the overall pipeline, with an at-a-glance overview of all products in therapeutic development for each indication
- Assess the products in development in granular detail, with an up-to-date overview of each individual pipeline program in each indication and a comprehensive picture of recent updates and milestones for each
- Analyze the companies, institutions and universities currently operating in the pipeline and the products being fielded by each of these
- Understand the composition of the pipeline in terms of molecule type, molecular target, mechanism of action and route of administration
Summary
This report provides an overview of the pipeline landscape for mosquito-borne diseases and comprehensive information on the therapeutics under development and key players involved in therapeutic development for West Nile virus infections, Japanese encephalitis, yellow fever and malaria. It also features dormant and discontinued products.
West Nile infection, Japanese encephalitis and yellow fever are all caused by flaviviruses, whereas malaria is caused by a parasite (Plasmodium). Symptoms of West Nile infection include a fever, headache, body aches, skin rash, and swollen lymph glands. There are 18 products in development for this indication.
Japanese encephalitis affects the membranes around the brain. Symptoms include fever, headache, muscle pain, diarrhea, seizures, muscle weakness and paralysis. There are 17 products in development for this indication.
Yellow fever is an acute systemic illness (hemorrhagic fever). Symptoms include irregular heartbeats, bleeding, vomiting, coma, delirium, fever, headache and muscle aches. There are 15 products in development for this indication.
Malaria is a life-threatening blood disease. Symptoms may include fever, chills, headache, sweats, fatigue, enlarged spleen, nausea and vomiting. There are 206 products in development for this indication.
Molecular targets acted on by products in development for mosquito-borne diseases include interferon receptors, toll-like receptors and pathogen proteins such as Plasmodium falciparum merozoite surface proteins. Companies operating in this pipeline space include Sanaria, Medigen and Ology Bioservices.
Scope
- Which companies are the most active within each pipeline?
- Which pharmaceutical approaches are the most prominent at each stage of the pipeline and within each indication?
- To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies?
- What are the most important R&D milestones and data publications to have happened in this disease area?
Reasons to buy
- Understand the overall pipeline, with an at-a-glance overview of all products in therapeutic development for each indication
- Assess the products in development in granular detail, with an up-to-date overview of each individual pipeline program in each indication and a comprehensive picture of recent updates and milestones for each
- Analyze the companies, institutions and universities currently operating in the pipeline and the products being fielded by each of these
- Understand the composition of the pipeline in terms of molecule type, molecular target, mechanism of action and route of administration
Frequently Asked Questions
This market study covers the global and regional market with an in-depth analysis of the overall growth prospects in the market. Furthermore, it sheds light on the comprehensive competitive landscape of the global market. The report further offers a dashboard overview of leading companies encompassing their successful marketing strategies, market contribution, recent developments in both historic and present contexts.
- By product type
- By End User/Applications
- By Technology
- By Region
The report provides a detailed evaluation of the market by highlighting information on different aspects which include drivers, restraints, opportunities, and threats. This information can help stakeholders to make appropriate decisions before investing.
